Seminars in Nephrology
Volume 24, Issue 5 , Pages 417-422 , September 2004

Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients

  • Pietro Pozzoni

      Affiliations

    • Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy.
    • ,
  • Marco Pozzi

      Affiliations

    • Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy.
    • ,
  • Lucia Del Vecchio

      Affiliations

    • Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy.
    • ,
  • Francesco Locatelli

      Affiliations

    • Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy.
    • Corresponding Author InformationAddress reprint requests to Professor Dr. Francesco Locatelli, Department of Nephrology and Dialysis, A. Manzoni Hospital, Via dell’Eremo 9/11, 23900 Lecco, Italy.

References 

  1. US Renal Data System . 2002 Annual Data Report . Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002;
  2. Locatelli F , Marcelli D , Conte F , et al.   Cardiovascular disease in chronic renal failure: The challenge continues. Registro Lombardo Dialisi e Trapianto . Nephrol Dial Transplant . 2000;15(suppl 5):69–80
  3. Foley RN , Parfrey PS , Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal disease . Am J Kidney Dis . 1998;32(suppl 3):S112–S119
  4. Foley RN , Parfrey PS , Harnett JD , et al.   Clinical and echocardiographic disease in patients starting end-stage renal disease therapy . Kidney Int . 1995;47:186–192
  5. Locatelli F , Marcelli D , Conte F , et al.   Patient selection affects end-stage renal disease outcome comparisons . Kidney Int . 2000;57(suppl 74):S94–S99
  6. Locatelli F , Hannedouche T , Jacobson SH , et al.   Risk factors for cardiovascular diseases in patients starting dialysis in Northern and Southern Europe (Results from the MPO study) . Nephrol Dial Transplant . 2002;17:A11; (abstr)
  7. Jager KJ , Merkus MP , Boeschoten EW , et al.   Dialysis in the Netherlands (The clinical condition of new patients put into a European perspective) . Nephrol Dial Transplant . 1999;14:2438–2444
  8. Locatelli F , Port FK , Pisoni RL , et al.   Patient and treatment characteristics in the MPO study (Validation against the DOPPS population) . Nephrol Dial Transplant . 2003;18:A196; (abstr)
  9. Locatelli F , Marcelli D , Conte F , et al.   Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease . J Am Soc Nephrol . 2001;12:2411–2417
  10. Levin A , Thompson CR , Ethier J , et al.   Left ventricular mass index increase in early renal disease (Impact of decline in hemoglobin) . Am J Kidney Dis . 1999;34:125–134
  11. Drueke T , Locatelli F , Clyne N , et al.   Cardiovascular disease characteristics of chronic kidney disease patients enrolled in the ‘Cardiovascular Risk Reduction by Early Anaemia Treatment with Epoetin Beta’ (CREATE) study . Nephrol Dial Transplant . 2003;18:A156; (abstr)
  12. Culleton BF , Larson MG , Wilson PW , et al.   Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency . Kidney Int . 1999;56:2214–2219
  13. Ruilope LM , Salvetti A , Jamerson K , et al.   Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study . J Am Soc Nephrol . 2001;12:218–225
  14. Levin A . Anemia and left ventricular hypertrophy in chronic kidney disease populations (A review of the current state of knowledge) . Kidney Int . 2002;61(suppl 80):S35–S38
  15. Astor BC , Muntner P , Levin A , et al.   Association of kidney function with anemia (The Third National Health and Nutrition Examination Survey (1988–1994)) . Arch Intern Med . 2002;162:1401–1408
  16. Locatelli F , Pisoni RL , Combe C , et al.   Anaemia in haemodialysis patients of five European countries (association with morbidity and mortality in the Dialysis Outcomes and Practices Patterns Study (DOPPS)) . Nephrol Dial Transplant . 2004;19:121–132
  17. Valderrabano F , Horl WH , Macdougall IC , et al.   PRE-dialysis survey on anaemia management . Nephrol Dial Transplant . 2003;18:89–8100
  18. Locatelli F , Conte F , Marcelli D . The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity—the experience of the Lombardy Dialysis Registry . Nephrol Dial Transplant . 1998;13:1642–1644
  19. Ma JZ , Ebben J , Xia H , et al.   Haematocrit level and associated mortality in haemodialysis patients . J Am Soc Nephrol . 1999;10:610–619
  20. Xia H , Ebben J , Ma JZ , et al.   Haematocrit level and hospitalizations risks in haemodialysis patients . J Am Soc Nephrol . 1999;10:1309–1316
  21. Collins AJ , Li S , St Peter W , et al.   Death, hospitalization and economic associations among incident hemodialysis patients with hematocrit values of 36–39% . J Am Soc Nephrol . 2001;12:2465–2473
  22. Holland DC , Lam M . Predictors of hospitalization and death among pre-dialysis patients (A retrospective cohort study) . Nephrol Dial Transplant . 2000;15:650–658
  23. Silberberg JS , Barre PE , Prichard SS , et al.   Impact of left ventricular hypertrophy on survival in end-stage renal disease . Kidney Int . 1989;36:286–290
  24. London GM , Fabiani F , Marchais SJ , et al.   Uremic cardiomyopathy (An inadequate left ventricular hypertrophy) . Kidney Int . 1987;31:973–980
  25. Foley RN , Parfrey PS , Harnett JD , et al.   The impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease . Am J Kidney Dis . 1996;28:53–61
  26. Portoles J , Torralbo A , Martin P , et al.   Cardiovascular effects of recombinant human erythropoietin in predialysis patients . Am J Kidney Dis . 1997;29:541–548
  27. Hayashi T , Suzuki A , Shoji T , et al.   Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure . Am J Kidney Dis . 2000;35:250–256
  28. Silverberg DS , Wexler D , Blum M , et al.   The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron . Nephrol Dial Transplant . 2003;18:141–146
  29. Foley RN , Parfrey PS , Morgan J , et al.   Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy . Kidney Int . 2000;58:1325–1335
  30. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000 . Am J Kidney Dis . 2001;37(suppl 1):S182–S238
  31. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure . Nephrol Dial Transplant . 2004;19(suppl 2):1–47
  32. Tonelli M , Winkelmayer WC , Jindal KK , et al.   The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients . Kidney Int . 2003;64:295–304
  33. Besarab A , Bolton WK , Browne JK , et al.   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin . N Engl J Med . 1998;339:584–590
  34. Moreno F , Sanz-Guajardo D , Lopez-Gomez JM , et al.   Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients . J Am Soc Nephrol . 2000;11:335–342
  35. Furuland H , Linde T , Ahlmen J , et al.   A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients . Nephrol Dial Transplant . 2003;18:353–361
  36. Block GA , Hulbert-Shearon TE , Levin NW , et al.   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients (a national study) . Am J Kidney Dis . 1998;31:607–617
  37. Raggi P , Boulay A , Chasan-Taber S , et al.   Cardiac calcification in adult hemodialysis patients (A link between end-stage renal disease and cardiovascular disease?) . J Am Coll Cardiol . 2002;39:695–701
  38. Goodman WG , Goldin J , Kuizon BD , et al.   Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis . N Engl J Med . 2000;342:1478–1483
  39. Chertow GM , Burke SK , Raggi P  Treat to Goal Working Group . Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients . Kidney Int . 2002;62:245–252
  40. Katsumata K , Kusano K , Hirata M , et al.   Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats . Kidney Int . 2003;64:441–450
  41. Jungers P , Massy ZA , Khoa TN , et al.   Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients (A prospective study) . Nephrol Dial Transplant . 1997;12:2597–2602
  42. Levey AS , Beto JA , Coronado BE , et al.  National Kidney Foundation Task Force on Cardiovascular disease   Controlling the epidemic of cardiovascular disease in chronic renal disease (What do we know? What do we need to learn? Where do we go from here?) . Am J Kidney Dis . 1998;32:853–906
  43. Wanner C , Krane V , Ruf G , et al.  Die Deutsche Diabetes Dialyse Studie Investigators   Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis . Kidney Int . 1999;56(suppl 71):S222–S226
  44. Bostom AG , Culleton BF . Hyperhomocysteinemia in chronic renal disease . J Am Soc Nephrol . 1999;10:891–900
  45. Stenvinkel P . Inflammation in end-stage renal failure (Could it be treated?) . Nephrol Dial Transplant . 2002;17(suppl 8):S33–S38
  46. Zimmermann J , Herrlinger S , Pruy A , et al.   Inflammation enhances cardiovascular risk and mortality in hemodialysis patients . Kidney Int . 1999;55:648–658
  47. Iseki K , Tozawa M , Yoshi S , et al.   Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients . Nephrol Dial Transplant . 1999;14:1956–1960
  48. Yeun JY , Levine RA , Mantadilok V , et al.   C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients . Am J Kidney Dis . 2000;35:469–476
  49. Locatelli F , Canaud B , Eckardt KU , et al.   Oxidative stress in end-stage renal disease (An emerging threat to patient outcome) . Nephrol Dial Transplant . 2003;18:1272–1280
  50. Boaz M , Matas Z , Biro A , et al.   Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis . Kidney Int . 1999;56:1078–1083
  51. Boaz M , Smetana S , Weinstein T , et al.   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) (Randomised placebo-controlled trial) . Lancet . 2000;356:1213–1218

PII: S0270-9295(04)00095-6

doi: 10.1016/j.semnephrol.2004.06.012

Seminars in Nephrology
Volume 24, Issue 5 , Pages 417-422 , September 2004

Article Tools

* Image Usage & Resolution